Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review)

Shigetomi,Hiroshi; Higashiura,Yumi; Kajihara,Hirotaka; Kobayashi,Hiroshi

doi:10.3892/or.2012.1833

Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review)

Authors:
- Hiroshi Shigetomi
- Yumi Higashiura
- Hirotaka Kajihara
- Hiroshi Kobayashi
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Nara Medical University, Nara 634-8522, Japan
Published online on: May 25, 2012 https://doi.org/10.3892/or.2012.1833
Pages: 395-408

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Identification of the potential gene expression profiles of epithelial ovarian cancer and the arrival of newly targeted therapies have advanced the strategies used for treatment of this disease. This review focuses on the design of ongoing and planned clinical trials and offers a synopsis of the English-language literature for preclinical and clinical targeted therapies for epithelial ovarian cancer. Among many targeted agents, a promising, novel class of targeted drugs for special patient populations expected to improve the effectiveness of current therapy include inhibitors of angiogenesis, poly (ADP ribose) polymerase (PARP) and DNA repair mechanisms. Inhibition of PARP or homologous recombination (HR) repair mediated by Chk1 (checkpoint kinase 1) would selectively sensitize p53 mutation, BRCAness phenotype (serous type ovarian cancer) or HNF (hepatocyte nuclear factor)-1β-overexpressing tumor cells (clear cell type ovarian cancer) to chemotherapeutic agents. The therapeutic response is likely to be limited to a targeted patient, but not to the broad population. This review discusses some of the key current developments and existing challenges.

View Figures

View References

1	Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S and Morrison J: Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 9:CD0079302011.PubMed/NCBI
2	Banerjee S and Kaye S: The role of targeted therapy in ovarian cancer. Eur J Cancer. 47(Suppl 3): S116–S130. 2011. View Article : Google Scholar
3	Oei AL, Sweep FC, Thomas CM, Boerman OC and Massuger LF: The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (Review). Int J Oncol. 32:1145–1157. 2008. View Article : Google Scholar : PubMed/NCBI
4	Reichert JM: Antibody-based therapeutics to watch in 2011. MAbs. 3:76–99. 2011. View Article : Google Scholar : PubMed/NCBI
5	Itamochi H: Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World J Biol Chem. 1:209–220. 2010. View Article : Google Scholar : PubMed/NCBI
6	Richardson DL, Backes FJ, Seamon LG, et al: Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 111:461–466. 2008. View Article : Google Scholar : PubMed/NCBI
7	Jurado JM, Sánchez A, Pajares B, Pérez E, Alonso L and Alba E: Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol. 10:583–586. 2008. View Article : Google Scholar : PubMed/NCBI
8	Perren TJ, Swart AM, Pfisterer J, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 365:2484–2496. 2011. View Article : Google Scholar : PubMed/NCBI
9	Köhne CH: How to integrate molecular targeted agents in the continuum of care. Ann Oncol. 21(Suppl 7): vii134–vii139. 2010.PubMed/NCBI
10	Moroney JW, Sood AK and Coleman RL: Aflibercept in epithelial ovarian carcinoma. Future Oncol. 5:591–600. 2009. View Article : Google Scholar : PubMed/NCBI
11	Teng LS, Jin KT, He KF, Zhang J, Wang HH and Cao J: Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc. 73:449–456. 2010. View Article : Google Scholar : PubMed/NCBI
12	Colombo N, Mangili G, Mammoliti S, et al: A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol. 125:42–47. 2012. View Article : Google Scholar : PubMed/NCBI
13	Coleman RL, Duska LR, Ramirez PT, et al: Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 12:1109–1117. 2011.
14	Neal J and Wakelee H: AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Curr Opin Mol Ther. 12:487–495. 2010.PubMed/NCBI
15	Karlan BY, Oza AM, Richardson GE, et al: Randomized, double-blind, placebo-controlled phase II Study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 30:362–371. 2012. View Article : Google Scholar : PubMed/NCBI
16	Yarom N and Jonker DJ: The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med. 11:95–105. 2011.PubMed/NCBI
17	Steffensen KD, Waldstrøm M, Jeppesen U, Jakobsen E, Brandslund I and Jakobsen A: The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer. 17:798–807. 2007. View Article : Google Scholar : PubMed/NCBI
18	Farley J, Fuchiuji S, Darcy KM, et al: Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol. 113:341–347. 2009. View Article : Google Scholar
19	Tang L and Zhao X: Polyclonal antitumor immunoglobulin may play a role in ovarian cancer adjuvant therapy. Med Hypotheses. 76:530–532. 2011. View Article : Google Scholar : PubMed/NCBI
20	Makhija S, Amler LC, Glenn D, et al: Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 28:1215–1223. 2010. View Article : Google Scholar : PubMed/NCBI
21	Langdon SP, Faratian D, Nagumo Y, Mullen P and Harrison DJ: Pertuzumab for the treatment of ovarian cancer. Expert Opin Biol Ther. 10:1113–1120. 2010. View Article : Google Scholar : PubMed/NCBI
22	Sheng Q, Liu X, Fleming E, et al: An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 17:298–310. 2010. View Article : Google Scholar : PubMed/NCBI
23	Konner JA, Bell-McGuinn KM, Sabbatini P, et al: Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 16:5288–5295. 2010. View Article : Google Scholar
24	Berek J, Taylor P, McGuire W, Smith LM, Schultes B and Nicodemus CF: Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 27:418–425. 2009. View Article : Google Scholar : PubMed/NCBI
25	Sabbatini P, Dupont J, Aghajanian C, et al: Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res. 12:5503–5510. 2006. View Article : Google Scholar : PubMed/NCBI
26	Grisham RN, Berek J, Pfisterer J and Sabbatini P: Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 3:153–162. 2011. View Article : Google Scholar : PubMed/NCBI
27	Ruf P and Lindhofer H: Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 98:2526–2534. 2001. View Article : Google Scholar : PubMed/NCBI
28	Baumann K, Pfisterer J, Wimberger P, et al: Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol. 123:27–32. 2011. View Article : Google Scholar
29	Bell-McGuinn KM, Matthews CM, Ho SN, et al: A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 121:273–279. 2011.
30	Matei D, Sill MW, Lankes HA, et al: Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol. 29:69–75. 2011. View Article : Google Scholar : PubMed/NCBI
31	Bodnar L, Górnas M and Szczylik C: Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecol Oncol. 123:33–36. 2011. View Article : Google Scholar : PubMed/NCBI
32	Ramasubbaiah R, Perkins SM, Schilder J, et al: Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol. 123:499–504. 2011. View Article : Google Scholar : PubMed/NCBI
33	Welch SA, Hirte HW, Elit L, et al: Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer. 20:787–793. 2010. View Article : Google Scholar : PubMed/NCBI
34	Pölcher M, Eckhardt M, Coch C, et al: Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol. 66:203–207. 2010.PubMed/NCBI
35	Eichbaum M, Mayer C, Eickhoff R, et al: The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer. 11:4532011. View Article : Google Scholar : PubMed/NCBI
36	Friedlander M, Hancock KC, Rischin D, et al: A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 119:32–37. 2010. View Article : Google Scholar : PubMed/NCBI
37	Patel BB, He YA, Li XM, et al: Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics. 5:137–149. 2008.PubMed/NCBI
38	Santen RJ, Brodie H, Simpson ER, Siiteri PK and Brodie A: History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev. 30:343–375. 2009. View Article : Google Scholar : PubMed/NCBI
39	Juretzka M, Hensley ML, Tew W, et al: A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. Eur J Gynaecol Oncol. 29:568–572. 2008.PubMed/NCBI
40	Blank SV, Christos P, Curtin JP, et al: Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol. 119:451–456. 2010. View Article : Google Scholar : PubMed/NCBI
41	Nimeiri HS, Oza AM, Morgan RJ, et al: Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 110:49–55. 2008. View Article : Google Scholar : PubMed/NCBI
42	Garcia AA, Sill MW, Lankes HA, et al: A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study. Gynecol Oncol. 124:569–574. 2012. View Article : Google Scholar : PubMed/NCBI
43	Kimball KJ, Numnum TM, Kirby TO, et al: A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol. 111:95–101. 2008. View Article : Google Scholar : PubMed/NCBI
44	Weroha SJ, Oberg AL, Ziegler KL, et al: Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol. 122:116–120. 2011. View Article : Google Scholar : PubMed/NCBI
45	Murphy M and Stordal B: Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resist Updat. 14:177–190. 2011. View Article : Google Scholar : PubMed/NCBI
46	Gnoni A, Marech I, Silvestris N, Vacca A and Lorusso V: Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets. 12:563–578. 2011. View Article : Google Scholar : PubMed/NCBI
47	Le XF, Mao W, Lu Z, Carter BZ and Bast RC Jr: Dasatinib induces autophagic cell death in human ovarian cancer. Cancer. 116:4980–4990. 2010. View Article : Google Scholar : PubMed/NCBI
48	Oza AM, Elit L, Tsao MS, et al: Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 29:3278–3285. 2011. View Article : Google Scholar : PubMed/NCBI
49	Behbakht K, Sill MW, Darcy KM, et al: Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 123:19–26. 2011. View Article : Google Scholar
50	Temkin SM, Yamada SD and Fleming GF: A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol. 117:473–476. 2010. View Article : Google Scholar : PubMed/NCBI
51	Kollmannsberger C, Hirte H, Siu LL, et al: Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Ann Oncol. 23:238–244. 2012. View Article : Google Scholar : PubMed/NCBI
52	Janku F, Wheler JJ, Westin SN, et al: PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 30:777–782. 2012. View Article : Google Scholar : PubMed/NCBI
53	Radosa MP, Häfner N, Camara O, et al: Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer. Int J Gynecol Cancer. 21:1399–1406. 2011. View Article : Google Scholar
54	Narod SA: BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol. 7:702–707. 2010. View Article : Google Scholar : PubMed/NCBI
55	Javle M and Curtin NJ: The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol. 3:257–267. 2011. View Article : Google Scholar : PubMed/NCBI
56	Lord CJ and Ashworth A: Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol. 8:363–369. 2008. View Article : Google Scholar : PubMed/NCBI
57	Turner N, Tutt A and Ashworth A: Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 4:814–819. 2004.
58	Penning TD: Small-molecule PARP modulators - current status and future therapeutic potential. Curr Opin Drug Discov Devel. 13:577–586. 2010.PubMed/NCBI
59	Fong PC, Yap TA, Boss DS, et al: Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 28:2512–2519. 2010. View Article : Google Scholar : PubMed/NCBI
60	Gelmon KA, Tischkowitz M, Mackay H, et al: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12:852–861. 2011. View Article : Google Scholar
61	Welch S, Hirte HW, Carey MS, et al: UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol. 106:305–310. 2007. View Article : Google Scholar : PubMed/NCBI
62	Morgan MA, Parsels LA, Zhao LP, et al: Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 70:4972–4981. 2010. View Article : Google Scholar : PubMed/NCBI
63	Kajihara H, Yamada Y, Kanayama S, et al: Clear cell carcinoma of the ovary: potential pathogenic mechanisms (Review). Oncol Rep. 23:1193–1203. 2010.PubMed/NCBI
64	Yamada Y, Shigetomi H, Onogi A, et al: Redox-active iron-induced oxidative stress in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer. 21:1200–1207. 2011.PubMed/NCBI
65	Smyth JF, Gourley C, Walker G, et al: Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res. 13:3617–3622. 2007. View Article : Google Scholar : PubMed/NCBI
66	Fang F, Balch C, Schilder J, et al: A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer. 116:4043–4053. 2010. View Article : Google Scholar : PubMed/NCBI
67	Modesitt SC, Sill M, Hoffman JS and Bender DP; Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 109:182–186. 2008. View Article : Google Scholar : PubMed/NCBI
68	Tutt A, Robson M, Garber JE, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 376:235–244. 2010. View Article : Google Scholar
69	Itamochi H, Yoshida T, Walker CL, et al: Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 122:641–647. 2011. View Article : Google Scholar : PubMed/NCBI
70	Vance S, Liu E, Zhao L, et al: Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle. 10:4321–4329. 2011. View Article : Google Scholar : PubMed/NCBI